[Chimeric antigen receptors (CARs): universal tools in adoptive cell therapy]

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Tumor-infiltrating lymphocytes (TIL) can control tumors, inspiring the redirection of cytolytic T-cells using specific receptors.
• The development of chimeric antigen receptors (CARs) aims to enhance anti-tumor immunity.

Purpose of the Study:

• To develop a recombinant receptor-signal molecule (CAR) for increased selectivity and enhanced anti-tumor immunity.
• To explore the modular composition and development of CAR technology for adoptive immune cell therapy.

Main Methods:

• Description of a prototype CAR.
• Overview of CAR technology's modular composition and development.
• Application in adoptive immune cell therapy.

Main Results:

• CAR T-cell activation is influenced by binding affinity, target antigen epitope, expression density, accessibility, and signaling domains.
• CAR modular composition modulates T-cell response quality and duration.
• CAR T-cells can function as "biopharmaceutical factories" (TRUCKs) releasing therapeutic proteins.

Conclusions:

• CAR T-cell therapy is effective for hematological malignancies but faces challenges with solid tumors.
• Allogeneic CAR T-cell technology offers "off-the-shelf" solutions for broader patient access.
• CAR T-cells present therapeutic potential for autoimmune diseases.